Page 18 - 《中国药科大学学报》2025年第4期

414 学报 Journal of China Pharmaceutical University 2025, 56(4): 405 − 415 第 56 卷

regulation of immune cell function and therapeutic [38] Kwon J, Bakhoum SF. The cytosolic DNA-sensing cGAS-
implications[J]. J Immunol, 2022, 209(5): 845-854. STING pathway in cancer[J]. Cancer Discov, 2020, 10(1): 26-
[23] Nguyen TA, Smith BRC, Elgass KD, et al. SIDT1 localizes to 39.
endolysosomes and mediates double-stranded RNA transport in- [39] Meric-Bernstam F, Sweis RF, Hodi FS, et al. Phase I dose-esca-
to the cytoplasm[J]. J Immunol, 2019, 202(12): 3483-3492. lation trial of MIW815 (ADU-S100), an intratumoral STING
[24] Yuen MF, Chen CY, Liu CJ, et al. A phase 2, open-label, ran- agonist, in patients with advanced/metastatic solid tumors or
domized, multiple-dose study evaluating Inarigivir in treatment- lymphomas[J]. Clin Cancer Res, 2022, 28(4): 677-688.
naïve patients with chronic hepatitis B[J]. Liver Int, 2023, 43(1): [40] Harrington KJ, Brody J, Ingham M, et al. LBA15 Preliminary
77-89. results of the first-in-human (FIH) study of MK-1454, an ago-
[25] Moreno V, Gaudy-Marqueste C, Wermke M, et al. 794 Safety nist of stimulator of interferon genes (STING), as monotherapy
and efficacy results from a phase 1/1b study of intratumoral or in combination with pembrolizumab (pembro) in patients
MK-4621, a retinoic acid-inducible gene I (RIG-I) agonist, plus with advanced solid tumors or lymphomas[J]. Ann Oncol, 2018,
intravenous pembrolizumab in patients with advanced solid tu- 29: viii712.
mors[C]//Late-breaking abstracts. BMJ Publishing Group Ltd, [41] Janku F, Luke JJ, Brennan A, et al. Abstract CT110: Intratu-
2020: A474.2-A475. moral injection of SYNB1891, a synthetic biotic designed to ac-
[26] Lamoot A, Jangra S, Laghlali G, et al. Lipid nanoparticle encap- tivate the innate immune system, demonstrates target engage-
sulation empowers poly(I: C) to activate cytoplasmic RLRs and ment in humans including intratumoral STING activation[J].
thereby increases its adjuvanticity[J]. Small, 2024, 20(10): Cancer Res, 2021, 81(13_Supplement): CT110.
e2306892. [42] Feng XD, Lin J, Jang SC, et al. 761 exoSTING demonstrates
[27] Steinberg GD, Kalota SJ, Lotan Y, et al. Clinical results of a potent anti-tumor activity in a mouse model of leptomeningeal
phase 1 study of intravesical EG-70 in patients with BCG-unre- disease[C]//Regular and Young Investigator Award Abstracts.
sponsive NMIBC[J]. J Clin Oncol, 2023, 41(6_suppl): 512. BMJ Publishing Group Ltd, 2021: A796-A796.
[28] Gokhale NS, Sam RK, Somfleth K, et al. Cellular RNA inter- [43] Foldi J, Piha-Paul SA, Villaruz LC, et al. A phase 1 dose-esca-
acts with MAVS to promote antiviral signaling[J]. Science, lation and expansion study of an intratumorally administered
2024, 386(6728): eadl0429. dual STING agonist (ONM-501) alone and in combination with
[29] Ashley CN, Broni E, Miller WA 3rd. ADAR family proteins: a cemiplimab in patients with advanced solid tumors and lym-
structural review[J]. Curr Issues Mol Biol, 2024, 46(5): 3919- phomas[J]. J Clin Oncol, 2024, 42(16_suppl): TPS2693.
3945. [44] Luke J J, Pinato D J, Juric D, et al. Phase I dose-escalation and
[30] Vogel OA, Han J, Liang CY, et al. The p150 isoform of pharmacodynamic study of STING agonist E7766 in advanced
ADAR1 blocks sustained RLR signaling and apoptosis during solid tumors[J]. J Immunothera Cancer, 2025, 13(2): e010511.
influenza virus infection[J]. PLoS Pathog, 2020, 16(9): [45] Pelka K, Shibata T, Miyake K, et al. Nucleic acid-sensing TLRs
e1008842. and autoimmunity: novel insights from structural and cell biolo-
[31] Wang X, Li JX, Zhu YS, et al. Targeting ADAR1 with a small gy[J]. Immunol Rev, 2016, 269(1): 60-75.
molecule for the treatment of prostate cancer[J]. Nat Cancer, [46] Alzahrani B. The biology of toll-like receptor 9 and its role in
2025, 6(3): 474-492. cancer[J]. Crit Rev Eukaryot Gene Expr, 2020, 30(5): 457-474.
[32] Patrick KL, Bell SL, Watson RO. For better or worse: cytosolic [47] Gies V, Bekaddour N, Dieudonné Y, et al. Beyond anti-viral ef-
DNA sensing during intracellular bacterial infection induces po- fects of chloroquine/hydroxychloroquine[J]. Front Immunol,
tent innate immune responses[J]. J Mol Biol, 2016, 428(17): 2020, 11: 1409.
3372-3386. [48] Borazanci EH, Jameson GS, Snyder CE, et al. Paclitaxel pro-
[33] Nakamura M, Takada T, Yamana K. Controlling Pyrene associ- tein bound (A) plus gemcitabine (G) plus cisplatin (C) and hy-
ation in DNA duplexes by B- to Z-DNA transitions[J]. Chem- droxychloroquine (HCQ) neoadjuvant therapy for localized pan-
biochem, 2019, 20(23): 2949-2954. creatic ductal adenocarcinoma (PDAC)[J]. J Clin Oncol, 2024,
[34] Smirnov E, Molínová P, Chmúrčiaková N, et al. Non-canonical 42(3_suppl): 667.
DNA structures in the human ribosomal DNA[J]. Histochem [49] Ribas A, Milhem MM, Hoimes CJ, et al. Phase 1b/2, open la-
Cell Biol, 2023, 160(6): 499-515. bel, multicenter, study of the combination of SD-101 and pem-
[35] Liu SD. Protein tyrosine phosphorylation in innate immune brolizumab in patients with advanced melanoma who are naïve
sensing of cytosolic nucleic acids [D]. Hangzhou: Zhejiang Uni- to anti-PD-1 therapy[J]. J Clin Oncol, 2018, 36(15_suppl):
versity, 2019. 9513.
[36] Lou FN, Zheng MY, Chen KX, et al. Research progress of [50] Paller AS, Browning J, Nikolic M, et al. Efficacy and tolerabili-
cGAS-STING signaling pathway modulators in immunothera- ty of the investigational topical cream SD-101 (6% allantoin) in
py[J]. J China Pharm Univ (中国药科大学学报), 2024, 55(1): patients with epidermolysis bullosa: a phase 3, randomized,
15-25. double-blind, vehicle-controlled trial (ESSENCE study)[J]. Or-
[37] Decout A, Katz J D, Venkatraman S, et al. The cGAS–STING phanet J Rare Dis, 2020, 15(1): 158.
pathway as a therapeutic target in inflammatory diseases[J]. Na- [51] Atreya R, Reinisch W, Peyrin-Biroulet L, et al. Clinical effica-
ture Reviews Immunology, 2021, 21(9): 548-569. cy of the Toll-like receptor 9 agonist cobitolimod using patient-